pfizer

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union

25/11/2021 MaP 0

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the […]

Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older

10/11/2021 MaP 0

Submission is based on efficacy and safety data from a Phase 3 randomized, controlled trial with more than 10,000 participants Data show a favorable safety […]

Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs

28/10/2021 MaP 0

PDF Version Doses expected to be delivered by April 2022 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government […]

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

16/08/2021 MaP 0

Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust […]

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa

22/07/2021 MaP 0

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) […]

Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2021 Tokyo Games

06/05/2021 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) […]

20/04/2021 MaP 0

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY® PDF Version European Union exercises option under previous agreement to […]

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months

01/04/2021 MaP 0

…Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective […]

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

25/02/2021 MaP 0

The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that […]

pharma.markets